奥氮平治疗首发精神分裂症的随访对照研究

A compartive Study of Olanzapine in the treatment of first-episode schizophrenia

目的探讨奥氮平与利培酮治疗首发精神分裂症的疗效及安全性。方法将148例首发精神分裂症患者随机分为研究组(奥氮平组)75例和对照组(利培酮组)73例,分别服用奥氮平、利培酮治疗。于治疗前及治疗第2月、4月、8月及12个月末采用阳性症状与阴性症状量表(PANSS)评定临床疗效,同时以社会功能缺陷筛选表(SDSS)评定社会功能;以副反应量表(TESS)评定不良反应。结果奥氮平组与利培酮组在痊愈率、显效率、PANSS评分与SDSS评分差异无统计学意义(P>0.05),奥氮平组在锥体外系反应、内分泌失调等方面少于利培酮组,在体质量增加方面多于利培酮组,差异具有统计学意义(P<0.05)。结论奥氮平和利培酮治疗首发精神分裂症疗效均好;但是奥氮平的不良反应少,安全性高,依从性好。

Objective To investigate the olanzapiue and risperidone in treatment of first-episode schizophrenia curative effect and the security. Methods 148 patients with first-episode schizophrenia patients were randomly divided into study group （olanzapine group） in 75 cases and the control group （73 eases, risperidone group） respectively taking olanzapine, risperidone treatment. To evaluate clinical efficacy, positive and negative symptoms scale （PANSS） forms have been used before the treatment and afte the treatment at the the end of the second, the forth, the eighth and twdveth month, aswell as using the social dysfunction screening scale （SDSS） form to assess the social function. Results the olanzapine and risperidone groups in cure rate, significant efficiency, PANSS score and SDSS score difference does not have statistical significance （P 〉 0.05）, the olanzapine group in extrapyramidal reactions, endocrine disorders, less than risperidone group, the increase in the body weight than risperidone group, the difference was statistically significant （P 〈 0.05）. Conclusion Both Olanzapine and risperidone in the treatment of first-episode schizophrenia curative effect are good; but olanzapine less adverse reaction, high safety, high compliance.